2014 Q4 Form 10-K Financial Statement
#000114420415018860 Filed on March 27, 2015
Income Statement
| Concept | 2014 Q4 | 2014 Q3 | 2014 Q2 |
|---|---|---|---|
| Revenue | $8.972M | $5.130M | $1.797M |
| YoY Change | -6.56% | -13.77% | -7.32% |
| Cost Of Revenue | $3.080M | $1.620M | $1.005M |
| YoY Change | 1.99% | -24.02% | -0.59% |
| Gross Profit | $5.896M | $3.510M | $792.0K |
| YoY Change | -10.49% | -8.04% | -14.66% |
| Gross Profit Margin | 65.72% | 68.42% | 44.07% |
| Selling, General & Admin | $6.160M | $2.792M | $3.656M |
| YoY Change | 7.32% | 16.48% | 50.45% |
| % of Gross Profit | 104.48% | 79.54% | 461.62% |
| Research & Development | $420.0K | $356.0K | $273.0K |
| YoY Change | 75.0% | 96.69% | 26.39% |
| % of Gross Profit | 7.12% | 10.14% | 34.47% |
| Depreciation & Amortization | $80.00K | $70.00K | $70.00K |
| YoY Change | 33.33% | 16.67% | 16.67% |
| % of Gross Profit | 1.36% | 1.99% | 8.84% |
| Operating Expenses | $6.570M | $6.725M | $3.929M |
| YoY Change | 10.05% | 160.86% | 48.49% |
| Operating Profit | -$674.0K | -$3.215M | -$3.137M |
| YoY Change | -209.24% | -359.48% | 82.6% |
| Interest Expense | $0.00 | $2.000K | $2.000K |
| YoY Change | -100.0% | -33.33% | 0.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$680.0K | -$3.216M | -$3.138M |
| YoY Change | -213.33% | -360.19% | 82.55% |
| Income Tax | $0.00 | $0.00 | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$676.0K | -$3.216M | -$3.138M |
| YoY Change | -213.23% | -359.98% | 82.55% |
| Net Earnings / Revenue | -7.53% | -62.69% | -174.62% |
| Basic Earnings Per Share | -$0.18 | -$0.19 | |
| Diluted Earnings Per Share | -$44.04K | -$176.8K | -$0.19 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 15.46M shares | 18.21M shares | 16.94K shares |
| Diluted Shares Outstanding | 18.21M shares | 16.94K shares |
Balance Sheet
| Concept | 2014 Q4 | 2014 Q3 | 2014 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $2.930M | $4.950M | $7.350M |
| YoY Change | 78.66% | 560.0% | 81.03% |
| Cash & Equivalents | $2.926M | $4.953M | $7.350M |
| Short-Term Investments | |||
| Other Short-Term Assets | $1.400M | $2.250M | $730.0K |
| YoY Change | -22.22% | 6.64% | 40.38% |
| Inventory | $3.292M | $4.180M | $3.248M |
| Prepaid Expenses | |||
| Receivables | $5.836M | $4.051M | $2.343M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $13.46M | $15.44M | $13.67M |
| YoY Change | 19.32% | 45.91% | 52.02% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.599M | $2.484M | $2.509M |
| YoY Change | 1.37% | -1.08% | 0.56% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $2.599M | $2.484M | $6.086M |
| YoY Change | -57.68% | -59.2% | 0.23% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $13.46M | $15.44M | $13.67M |
| Total Long-Term Assets | $2.599M | $2.484M | $6.086M |
| Total Assets | $16.06M | $17.92M | $19.76M |
| YoY Change | -7.82% | 7.52% | 31.15% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $667.0K | $2.108M | $1.399M |
| YoY Change | -34.03% | 62.4% | 36.22% |
| Accrued Expenses | $3.690M | $3.170M | $3.080M |
| YoY Change | 29.47% | 17.84% | 41.28% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $5.241M | $7.182M | $5.952M |
| YoY Change | 13.34% | 51.49% | 33.12% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $100.0K | $200.0K | $200.0K |
| YoY Change | -50.0% | -33.33% | -33.33% |
| Total Long-Term Liabilities | $100.0K | $200.0K | $200.0K |
| YoY Change | -50.0% | -33.33% | -33.33% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $5.241M | $7.182M | $5.952M |
| Total Long-Term Liabilities | $100.0K | $200.0K | $200.0K |
| Total Liabilities | $5.341M | $7.380M | $6.150M |
| YoY Change | 10.72% | 46.4% | 28.9% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$13.22M | -$12.54M | -$9.327M |
| YoY Change | 145.48% | 109.64% | 29.2% |
| Common Stock | $54.68M | $53.82M | $48.57M |
| YoY Change | 25.35% | 24.46% | 12.56% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | $30.74M | $30.74M | $25.64M |
| YoY Change | 19.91% | 19.91% | 0.0% |
| Treasury Stock Shares | 9.233M shares | 9.233M shares | 5.336M shares |
| Shareholders Equity | $10.72M | $10.54M | $13.61M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $16.06M | $17.92M | $19.76M |
| YoY Change | -7.82% | 7.52% | 31.15% |
Cashflow Statement
| Concept | 2014 Q4 | 2014 Q3 | 2014 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$676.0K | -$3.216M | -$3.138M |
| YoY Change | -213.23% | -359.98% | 82.55% |
| Depreciation, Depletion And Amortization | $80.00K | $70.00K | $70.00K |
| YoY Change | 33.33% | 16.67% | 16.67% |
| Cash From Operating Activities | -$1.740M | -$2.440M | -$1.990M |
| YoY Change | -302.33% | -25.15% | 729.17% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$190.0K | -$40.00K | -$60.00K |
| YoY Change | 58.33% | -42.86% | -75.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $0.00 | $10.00K | |
| YoY Change | |||
| Cash From Investing Activities | -$190.0K | -$40.00K | -$60.00K |
| YoY Change | 58.33% | -42.86% | -75.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | -100.0K | 80.00K | 3.880M |
| YoY Change | -166.67% | 300.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -1.740M | -2.440M | -1.990M |
| Cash From Investing Activities | -190.0K | -40.00K | -60.00K |
| Cash From Financing Activities | -100.0K | 80.00K | 3.880M |
| Net Change In Cash | -2.030M | -2.400M | 1.830M |
| YoY Change | -328.09% | -27.49% | -481.25% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.740M | -$2.440M | -$1.990M |
| Capital Expenditures | -$190.0K | -$40.00K | -$60.00K |
| Free Cash Flow | -$1.550M | -$2.400M | -$1.930M |
| YoY Change | -258.16% | -24.76% | -663142950502400300.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><u><font style="FONT-SIZE: 10pt">Concentration of Risks</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Future revenues, costs, margins and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the requirements associated with the development of OTC and other personal care products in order to continue to compete on a national and/or international level.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (“FDA”) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of December 31, 2014, our cash was $2.9 million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.1</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">626,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.4</font> million was uninsured.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Trade accounts receivable potentially subjects us to credit risk. We extend credit to our customers based upon an evaluation of the customer’s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many national chain, regional, specialty and local retail stores (see Note 11). During Fiscal 2014, 2013 and 2012, effectively all of our net revenues were related to domestic markets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our revenues are principally generated from the sale of OTC cold remedy products which approximated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 94</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% of total revenues for Fiscal 2014, 2013 and 2012, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Raw materials used in the production of the products are available from numerous sources. Certain raw material active ingredients used in connection with Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy products are purchased from a single unaffiliated supplier. Should the relationship terminate or the vendor become unable supply material, we believe that the current contingency plans would prevent a termination from materially affecting our operations. However, if the relationship was terminated, there may be delays in production of our products until an acceptable replacement supplier is located.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements and the accompanying notes thereto, in conformity with generally accepted accounting principles in the United States of America (“GAAP”), requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (“Sales Allowances”), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Our primary product, Cold-EEZE</font><sup style="font-style:normal"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">Ò</font></sup> <font style="FONT-SIZE: 10pt">Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy QuickMelts<sup style="font-style:normal">®</sup> and a Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (“Organix<sup style="font-style:normal">®</sup>”). Each of the Cold-EEZE<sup style="font-style:normal">®</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">®</sup> products, and Organix<sup style="font-style:normal">®</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1638000 | USD |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2926000 | USD |
| CY2013Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5319000 | USD |
| CY2014Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5836000 | USD |
| CY2013Q4 | us-gaap |
Inventory Net
InventoryNet
|
2521000 | USD |
| CY2014Q4 | us-gaap |
Inventory Net
InventoryNet
|
3292000 | USD |
| CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1801000 | USD |
| CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1404000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
11279000 | USD |
| CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
13458000 | USD |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2564000 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2599000 | USD |
| CY2013Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
3577000 | USD |
| CY2014Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
0 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
17420000 | USD |
| CY2014Q4 | us-gaap |
Assets
Assets
|
16057000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1011000 | USD |
| CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
667000 | USD |
| CY2013Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
2847000 | USD |
| CY2014Q4 | us-gaap |
Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
|
3685000 | USD |
| CY2013Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
766000 | USD |
| CY2014Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
889000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4624000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5241000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
200000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
|
100000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
200000 | USD |
| CY2014Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
100000 | USD |
| CY2013Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
11000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
13000 | USD |
| CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
43607000 | USD |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
54664000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-5385000 | USD |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-13219000 | USD |
| CY2013Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
25637000 | USD |
| CY2014Q4 | us-gaap |
Treasury Stock Value
TreasuryStockValue
|
30742000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
12596000 | USD |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
10716000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
17420000 | USD |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
16057000 | USD |
| CY2013Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
635000 | USD |
| CY2014Q4 | us-gaap |
Inventory Adjustments
InventoryAdjustments
|
797000 | USD |
| CY2014Q4 | us-gaap |
Cash Fdic Insured Amount
CashFDICInsuredAmount
|
626000 | USD |
| CY2014Q4 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
2400000 | USD |
| CY2014Q4 | us-gaap |
Due From Banks
DueFromBanks
|
3100000 | USD |
| CY2013 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
128000 | USD |
| CY2014 | us-gaap |
Sales Allowances Goods
SalesAllowancesGoods
|
129000 | USD |
| CY2010Q1 | us-gaap |
Variable Interest Entity Ownership Percentage
VariableInterestEntityOwnershipPercentage
|
0.5 | pure |
| CY2012 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
10200000 | USD |
| CY2013 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
10800000 | USD |
| CY2014 | us-gaap |
Marketing And Advertising Expense
MarketingAndAdvertisingExpense
|
10900000 | USD |
| CY2012 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1301000 | USD |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
824000 | USD |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1322000 | USD |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6628000 | USD |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6940000 | USD |
| CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4064000 | USD |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4341000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0005 | |
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
50000000 | shares |
| CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
21437059 | shares |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25125113 | shares |
| CY2013Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
5336053 | shares |
| CY2014Q4 | us-gaap |
Treasury Stock Shares
TreasuryStockShares
|
9232817 | shares |
| CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
350000 | USD |
| CY2014Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
372000 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
1125000 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
1125000 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
1025000 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
|
0 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
|
0 | USD |
| CY2014Q4 | us-gaap |
Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
|
3275000 | USD |
| CY2012Q4 | us-gaap |
Payments For Legal Settlements
PaymentsForLegalSettlements
|
2100000 | USD |
| CY2014Q4 | prph |
Additional Royalties And Commissions Accrual Interest Percentage
AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage
|
0.0325 | pure |
| CY2012 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2013 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
0 | USD |
| CY2014 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
100000 | USD |
| CY2012Q4 | prph |
Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
|
1000000 | USD |
| CY2012Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3500000 | USD |
| CY2014Q4 | prph |
Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
|
100000 | USD |
| CY2014Q4 | prph |
Additional Annual Installment Includes In Other Long Term Obligation
AdditionalAnnualInstallmentIncludesInOtherLongTermObligation
|
100000 | USD |
| CY2013 | us-gaap |
Litigation Settlement Interest
LitigationSettlementInterest
|
13000 | USD |
| CY2014 | us-gaap |
Litigation Settlement Interest
LitigationSettlementInterest
|
10000 | USD |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
15000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
420000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
148000 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P3Y | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P0Y | |
| CY2012 | prph |
Maximum Term Of Option From Date Of Grant
MaximumTermOfOptionFromDateOfGrant
|
P7Y | |
| CY2014 | prph |
Maximum Term Of Option From Date Of Grant
MaximumTermOfOptionFromDateOfGrant
|
P7Y | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.36 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.39 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.85 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.56 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.59 | |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P4Y6M | |
| CY2014 | us-gaap |
Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
|
P3Y6M | |
| CY2012 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0075 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0036 | pure |
| CY2014 | us-gaap |
Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
|
0.0010 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2013 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2014 | us-gaap |
Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2012 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.8306 | pure |
| CY2014 | us-gaap |
Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
|
0.5243 | pure |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1333000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1307000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1638000 | shares |
| CY2012 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2013 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
25000 | shares |
| CY2014 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
41000 | shares |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
64000 | shares |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
46000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1740000 | shares |
| CY2012 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
719000 | shares |
| CY2013 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
884000 | shares |
| CY2014 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingNumber
|
263000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
588000 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1085000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1477000 | shares |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
0 | shares |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
262000 | shares |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
20000 | shares |
| CY2011Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.88 | |
| CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.72 | |
| CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.60 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.64 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
1.08 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
8.11 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
4.53 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
9.50 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.40 | |
| CY2012 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
1.01 | |
| CY2013 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
1.32 | |
| CY2014 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Subject To Future Vesting Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedSubjectToFutureVestingWeightedAverageExercisePrice
|
0 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
1477000 | shares |
| CY2014Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
1.37 | |
| CY2013 | prph |
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
|
0.15 | pure |
| CY2014 | prph |
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
|
0.15 | pure |
| CY2012Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
13000 | USD |
| CY2013Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
237000 | USD |
| CY2014Q4 | prph |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
|
87000 | USD |
| CY2014Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
137000 | USD |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
12000 | USD |
| CY2014 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y3M18D | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
472000 | USD |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
16000 | USD |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
456000 | USD |
| CY2014 | prph |
Sharebased Compensation Options Granted Subject To Vesting Date Of Grant Minimum Term
SharebasedCompensationOptionsGrantedSubjectToVestingDateOfGrantMinimumTerm
|
P6Y | |
| CY2014 | prph |
Sharebased Compensation Options Granted Subject To Vesting Date Of Grant Maximum Term
SharebasedCompensationOptionsGrantedSubjectToVestingDateOfGrantMaximumTerm
|
P7Y | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
1.54 | |
| CY2014Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
262750 | shares |
| CY2012 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
104000 | USD |
| CY2013 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
100000 | USD |
| CY2014 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
101000 | USD |
| CY2010 | prph |
Payments To Fund Joint Venture Investments
PaymentsToFundJointVentureInvestments
|
500000 | USD |
| CY2010 | prph |
Maximum Amount Committed Towards Contributions In Joint Venture
MaximumAmountCommittedTowardsContributionsInJointVenture
|
2000000 | USD |
| CY2010 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
3600000 | USD |
| CY2010 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P12Y6M | |
| CY2010 | prph |
Ownership Percentage In Joint Venture
OwnershipPercentageInJointVenture
|
0.5 | pure |
| CY2012 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
22406000 | USD |
| CY2013 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
25032000 | USD |
| CY2014 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
22070000 | USD |
| CY2012 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8154000 | USD |
| CY2013 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
8361000 | USD |
| CY2014 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
7891000 | USD |
| CY2012 | us-gaap |
Gross Profit
GrossProfit
|
14252000 | USD |
| CY2013 | us-gaap |
Gross Profit
GrossProfit
|
16671000 | USD |
| CY2014 | us-gaap |
Gross Profit
GrossProfit
|
14179000 | USD |
| CY2012 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
8946000 | USD |
| CY2013 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9538000 | USD |
| CY2014 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
8965000 | USD |
| CY2012 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6127000 | USD |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5893000 | USD |
| CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8143000 | USD |
| CY2012 | prph |
Settlement Benefit
SettlementBenefit
|
1024000 | USD |
| CY2013 | prph |
Settlement Benefit
SettlementBenefit
|
0 | USD |
| CY2014 | prph |
Settlement Benefit
SettlementBenefit
|
0 | USD |
| CY2012 | us-gaap |
Operating Expenses
OperatingExpenses
|
15350000 | USD |
| CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
16255000 | USD |
| CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
22007000 | USD |
| CY2012 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-1098000 | USD |
| CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
416000 | USD |
| CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7828000 | USD |
| CY2012 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
7000 | USD |
| CY2013 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
2000 | USD |
| CY2014 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
4000 | USD |
| CY2012 | us-gaap |
Interest Expense
InterestExpense
|
0 | USD |
| CY2013 | us-gaap |
Interest Expense
InterestExpense
|
13000 | USD |
| CY2014 | us-gaap |
Interest Expense
InterestExpense
|
10000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-1091000 | USD |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
405000 | USD |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-7834000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1091000 | USD |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
405000 | USD |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7834000 | USD |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.07 | |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
0.03 | |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
|
-0.47 | |
| CY2012 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.07 | |
| CY2013 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.03 | |
| CY2014 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.47 | |
| CY2012 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
14843000 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15839000 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16773000 | shares |
| CY2012 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
14843000 | shares |
| CY2013 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16276000 | shares |
| CY2014 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16773000 | shares |
| CY2012 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2013 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2014 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
0 | USD |
| CY2012 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-618000 | USD |
| CY2013 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
1216000 | USD |
| CY2014 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-2471000 | USD |
| CY2012 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
1377000 | USD |
| CY2013 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-999000 | USD |
| CY2014 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-74000 | USD |
| CY2012 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
759000 | USD |
| CY2013 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
217000 | USD |
| CY2014 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-2545000 | USD |
| CY2012 | prph |
Income Taxes From Continuing Operations Of Current And Deferred Income Taxes
IncomeTaxesFromContinuingOperationsOfCurrentAndDeferredIncomeTaxes
|
759000 | USD |
| CY2013 | prph |
Income Taxes From Continuing Operations Of Current And Deferred Income Taxes
IncomeTaxesFromContinuingOperationsOfCurrentAndDeferredIncomeTaxes
|
217000 | USD |
| CY2014 | prph |
Income Taxes From Continuing Operations Of Current And Deferred Income Taxes
IncomeTaxesFromContinuingOperationsOfCurrentAndDeferredIncomeTaxes
|
-2545000 | USD |
| CY2012 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
759000 | USD |
| CY2013 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
217000 | USD |
| CY2014 | prph |
Income Taxes From Continuing Operations Before Valuation Allowances
IncomeTaxesFromContinuingOperationsBeforeValuationAllowances
|
-2545000 | USD |
| CY2012 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
759000 | USD |
| CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
217000 | USD |
| CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-2545000 | USD |
| CY2012 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2013 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2014 | us-gaap |
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-661000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
138000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-2662000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
1377000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
17000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
|
-51000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
43000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
62000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
|
168000 | USD |
| CY2012 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
759000 | USD |
| CY2013 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
217000 | USD |
| CY2014 | prph |
Income Tax Reconciliation Income Tax Expense Benefit Continuing Operations Before Valuation Allowance
IncomeTaxReconciliationIncomeTaxExpenseBenefitContinuingOperationsBeforeValuationAllowance
|
-2545000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-759000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-217000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
2545000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
6000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
7000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Meals And Entertainment
IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
|
7000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
-46000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
0 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
|
0 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Charitable Contributions
IncomeTaxReconciliationNondeductibleExpenseCharitableContributions
|
4000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Charitable Contributions
IncomeTaxReconciliationNondeductibleExpenseCharitableContributions
|
1000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Charitable Contributions
IncomeTaxReconciliationNondeductibleExpenseCharitableContributions
|
1000 | USD |
| CY2012 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
79000 | USD |
| CY2013 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
54000 | USD |
| CY2014 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
160000 | USD |
| CY2012Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
14158000 | USD |
| CY2013Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
13569000 | USD |
| CY2014Q4 | prph |
Deferred Tax Assets Operating Loss And Capital Loss Carry Forwards
DeferredTaxAssetsOperatingLossAndCapitalLossCarryForwards
|
14983000 | USD |
| CY2012Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
121000 | USD |
| CY2013Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
80000 | USD |
| CY2014Q4 | prph |
Deferred Tax Assets Consulting Royalty Costs
DeferredTaxAssetsConsultingRoyaltyCosts
|
39000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
819000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
|
752000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
-387000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
|
-483000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
60000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
-34000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
-45000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
983000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
1009000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
2508000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15322000 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
15056000 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
17754000 | USD |
| CY2012Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2013Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | USD |
| CY2014Q4 | prph |
Deferred Tax Benefits From Options And Warrants Exercises
DeferredTaxBenefitsFromOptionsAndWarrantsExercises
|
6700000 | USD |
| CY2012 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
271000 | USD |
| CY2013 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
266000 | USD |
| CY2014 | us-gaap |
Real Estate Owned Valuation Allowance Amounts Applied
RealEstateOwnedValuationAllowanceAmountsApplied
|
2700000 | USD |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1091000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
405000 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7834000 | USD |
| CY2012 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.07 | |
| CY2013 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.03 | |
| CY2014 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.47 | |
| CY2012 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2013 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2014 | prph |
Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
|
0 | USD |
| CY2012 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
0 | shares |
| CY2013 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
437000 | shares |
| CY2014 | prph |
Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
|
0 | shares |
| CY2012 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2013 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2014 | prph |
Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
|
0 | |
| CY2012 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-1091000 | USD |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
405000 | USD |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-7834000 | USD |
| CY2012 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.07 | |
| CY2013 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.03 | |
| CY2014 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.47 | |
| CY2013Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
7542000 | USD |
| CY2014Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
6171000 | USD |
| CY2013Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1939000 | USD |
| CY2014Q2 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
1797000 | USD |
| CY2013Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
5949000 | USD |
| CY2014Q3 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
5130000 | USD |
| CY2013Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
9602000 | USD |
| CY2014Q4 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
8972000 | USD |
| CY2013Q1 | us-gaap |
Gross Profit
GrossProfit
|
5339000 | USD |
| CY2014Q1 | us-gaap |
Gross Profit
GrossProfit
|
3980000 | USD |
| CY2013Q2 | us-gaap |
Gross Profit
GrossProfit
|
928000 | USD |
| CY2014Q2 | us-gaap |
Gross Profit
GrossProfit
|
792000 | USD |
| CY2013Q3 | us-gaap |
Gross Profit
GrossProfit
|
3817000 | USD |
| CY2014Q3 | us-gaap |
Gross Profit
GrossProfit
|
3510000 | USD |
| CY2013Q4 | us-gaap |
Gross Profit
GrossProfit
|
6587000 | USD |
| CY2014Q4 | us-gaap |
Gross Profit
GrossProfit
|
5896000 | USD |
| CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
290000 | USD |
| CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-804000 | USD |
| CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1719000 | USD |
| CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3138000 | USD |
| CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1237000 | USD |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3216000 | USD |
| CY2013Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
597000 | USD |
| CY2014Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-676000 | USD |
| CY2013Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.02 | |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-0.11 | |
| CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.08 | |
| CY2013Q4 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
0.04 | |
| CY2013Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.02 | |
| CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-0.11 | |
| CY2013Q3 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.08 | |
| CY2013Q4 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
0.04 | |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
| CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.18 | |
| CY2014Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
| CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11226000 | USD |
| CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
153000 | USD |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
160000 | USD |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
472000 | USD |
| CY2012 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
93000 | USD |
| CY2013 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
109000 | USD |
| CY2014 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
179000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
27000 | USD |
| CY2014 | us-gaap |
Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
|
0 | USD |
| CY2012 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1070000 | USD |
| CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
444000 | USD |
| CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
4910000 | USD |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11451000 | USD |
| CY2012 | us-gaap |
Depreciation
Depreciation
|
252000 | USD |
| CY2013 | us-gaap |
Depreciation
Depreciation
|
243000 | USD |
| CY2014 | us-gaap |
Depreciation
Depreciation
|
277000 | USD |
| CY2012 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2013 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
0 | USD |
| CY2014 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
6000 | USD |
| CY2012 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
246000 | USD |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
269000 | USD |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1044000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2190000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-90000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
517000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-637000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
470000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
771000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
940000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-886000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-397000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
411000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-285000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-344000 | USD |
| CY2012 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
-199000 | USD |
| CY2013 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
87000 | USD |
| CY2014 | prph |
Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
|
838000 | USD |
| CY2012 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
-2100000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
0 | USD |
| CY2014 | us-gaap |
Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
|
0 | USD |
| CY2012 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-269000 | USD |
| CY2013 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
88000 | USD |
| CY2014 | us-gaap |
Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
|
-123000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-5729000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
1137000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-3216000 | USD |
| CY2012 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
310000 | USD |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
442000 | USD |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
312000 | USD |
| CY2012 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | USD |
| CY2014 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
6000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-310000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-442000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-306000 | USD |
| CY2012 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
27000 | USD |
| CY2014 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD |
| CY2012 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1070000 | USD |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
444000 | USD |
| CY2014 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
4910000 | USD |
| CY2012 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
0 | USD |
| CY2013 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
100000 | USD |
| CY2014 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
100000 | USD |
| CY2012 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
1070000 | USD |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
371000 | USD |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
4810000 | USD |
| CY2012 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-4969000 | USD |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1066000 | USD |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
1288000 | USD |
| CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5541000 | USD |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
572000 | USD |
| CY2012 | us-gaap |
Interest Paid
InterestPaid
|
0 | USD |
| CY2013 | us-gaap |
Interest Paid
InterestPaid
|
13000 | USD |
| CY2014 | us-gaap |
Interest Paid
InterestPaid
|
10000 | USD |
| CY2012 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2013 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2014 | us-gaap |
Stock Issued1
StockIssued1
|
393000 | USD |
| CY2014 | dei |
Document Type
DocumentType
|
10-K | |
| CY2014 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-12-31 | |
| CY2014 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2014 | dei |
Entity Registrant Name
EntityRegistrantName
|
ProPhase Labs, Inc. | |
| CY2014 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0000868278 | |
| CY2014 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2014 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2014 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2014 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q2 | dei |
Entity Public Float
EntityPublicFloat
|
20476528 | USD |
| CY2014 | dei |
Trading Symbol
TradingSymbol
|
PRPH | |
| CY2015Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
15892296 | shares |
| CY2012 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD |
| CY2013 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | USD |
| CY2014 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
3577000 | USD |
| CY2012 | prph |
Treasury Stock Acquired Pursuant To Settlement Agreement
TreasuryStockAcquiredPursuantToSettlementAgreement
|
0 | USD |
| CY2013 | prph |
Treasury Stock Acquired Pursuant To Settlement Agreement
TreasuryStockAcquiredPursuantToSettlementAgreement
|
0 | USD |
| CY2014 | prph |
Treasury Stock Acquired Pursuant To Settlement Agreement
TreasuryStockAcquiredPursuantToSettlementAgreement
|
5105000 | USD |
| CY2012 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
246000 | USD |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
269000 | USD |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1000000 | USD |
| CY2014Q3 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
3600000 | USD |
| CY2009Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
45 | |
| CY2014 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
393000 | USD |
| CY2014 | prph |
Cash Less Exercise Of Right Terms
CashLessExerciseOfRightTerms
|
In the event of a cashless exercise of the Right, and the acquirer has acquired less than 50% beneficial ownership of the Company | |
| CY2014 | prph |
Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms
ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms
|
No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998. | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
|
200000 | shares |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
217000 | USD |
| CY2013Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
434000 | USD |
| CY2014Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
798000 | USD |
| CY2013Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
164000 | USD |
| CY2014Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
418000 | USD |
| CY2013Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
1923000 | USD |
| CY2014Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
2076000 | USD |
